Previous close | 16.27 |
Open | 16.29 |
Bid | 15.88 x 100 |
Ask | 15.95 x 800 |
Day's range | 15.77 - 16.50 |
52-week range | 11.09 - 18.22 |
Volume | |
Avg. volume | 1,517,324 |
Market cap | 1.879B |
Beta (5Y monthly) | 0.93 |
PE ratio (TTM) | 25.30 |
EPS (TTM) | 0.63 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 26.86 |
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult-to-treat diseases, today announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome ("LEMS") Awareness Day. This landmark event, now officially observed annually on March 30th
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst’s management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtual
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...